A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms BALANCE
- 04 Mar 2024 Planned primary completion date changed from 16 Feb 2024 to 31 Dec 2024.
- 14 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 27 Apr 2018 Status changed from not yet recruiting to recruiting.